Look back at pharma news in the week to October 16, 2020

18 October 2020

By Barbara Obstoj-Cardwell. Editor

Last week’s notable news included voluntary bankruptcy filing by Ireland-incorporated Mallinckrodt following a string of major problems for the company. On the coronavirus front, Johnson & Johnson joined AstraZeneca in calling a pause on clinical trials of its COVID-19 vaccine candidate JNJ-78436735 as a result of a safety issue, and then a similar situation arose with Eli Lilly's bamlanivimab (LY-CoV555) neutralizing antibody. There was also disappointing news from Vertex, which has discontinued its VX-814 program on safety concerns.

Mallinckrodt: Bankruptcy finalized

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK